Scholar Rock(SRRK) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For Q4 2025, the company reported operating expenses of $91.9 million, including $90.4 million in non-cash stock-based compensation, while excluding stock-based compensation, operating expenses were $72.5 million [26] - For the full year 2025, operating expenses totaled $384.6 million, with $75.6 million in non-cash stock-based compensation, and $309 million when excluding stock-based compensation [27] - The company ended 2025 with $368 million in cash and cash equivalents, bolstered by $60.4 million from the exercise of warrants [11][27] Business Line Data and Key Metrics Changes - The company is focused on the launch of apitegromab, the world's first muscle-targeted therapy for SMA, with preparations underway for a U.S. launch in 2026 [4][29] - The company is also advancing its anti-myostatin pipeline, including apitegromab and SRK-439, with ongoing clinical trials and promising data from phase I studies [10][20] Market Data and Key Metrics Changes - The SMA market is currently valued at nearly $5 billion in global annual sales, with a significant unmet need for muscle-targeted therapies as 95% of patients continue to experience muscle weakness [21][22] - The company is engaging with approximately 140 SMA treatment centers and 2,600 prescribing physicians in the U.S. to enhance disease education and awareness [22][23] Company Strategy and Development Direction - The company aims to deliver apitegromab to the SMA community as quickly as possible while also expanding its pipeline for other rare neuromuscular diseases [4][12] - The company is building a 50-country operating platform in Europe and enhancing its commercial capabilities to support the launch of apitegromab [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing engagement with the FDA and the urgency to bring apitegromab to market, reaffirming guidance for BLA resubmission and U.S. launch in 2026 [7][29] - The company is optimistic about the potential of its anti-myostatin pipeline and the significant opportunity to serve patients with SMA and other neuromuscular diseases [12][21] Other Important Information - The company secured a new debt facility for up to $550 million to support its commercial and R&D priorities, with $100 million immediately available for use [11][28] - The company is prepared to pivot to a second fill-finish facility if necessary, which would de-risk its supply chain for U.S. and EU launches [76] Q&A Session Summary Question: Is Novo now ready for re-inspection? - Management indicated that the gating item is a successful re-inspection of the Catalent Indiana facility, which would trigger the BLA resubmission [33][34] Question: What happens if the backup facility is needed? - Management believes that whether it is a supplemental BLA or a fallback to the backup facility, the timing would not be significantly altered [36][37] Question: What was the purpose of the FDA sending a field team? - Management noted that the field team's visit indicates the FDA's high priority on the remediation of the Catalent facility and the urgency to bring apitegromab to patients [40][42] Question: What are the expectations for the label regarding age subgrouping? - Management anticipates a straightforward alignment with the FDA on the final label after BLA resubmission, considering the data from previous trials [62] Question: What are the expectations for time to profitability? - Management expects a typical rare disease revenue trajectory leading to profitability within two to three years from launch, depending on pipeline progress [91]